CTI BIOPHARMA CORP (CTIC)
$9.05
Insights on CTI BIOPHARMA CORP
Increasing Revenue
Revenue is up for the last 5 quarters, 2.29M → 24.11M (in $), with an average increase of 35.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -15.70M → -21.79M (in $), with an average decrease of 18.0% per quarter
Performance
- $9.04$9.05$9.05
0.11%
Downside
Day's Volatility :0.11%
Upside
0.0%
- $4.01$9.05$9.05
55.69%
Downside
52 Weeks Volatility :55.69%
Upside
0.0%
Returns
| Period | CTI BIOPHARMA CORP | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 66.36% | 0.7% | -6.8% |
6 Months | 51.34% | -8.3% | -6.0% |
1 Year | 52.36% | -1.9% | -4.6% |
3 Years | 66.36% | 25.3% | 25.9% |
Highlights
Market Capitalization | 1.2B |
Book Value | - $0.19 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.54 |
PEG Ratio | 0.0 |
Wall Street Target Price | 10.49 |
Profit Margin | -91.38% |
Operating Margin TTM | -73.54% |
Return On Assets TTM | -28.58% |
Return On Equity TTM | -1018.75% |
Revenue TTM | 75.8M |
Revenue Per Share TTM | 0.62 |
Quarterly Revenue Growth YOY | 950.8% |
Gross Profit TTM | 50.4M |
EBITDA | -53.6M |
Diluted Eps TTM | -0.54 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.27 |
EPS Estimate Next Year | 0.27 |
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Next Quarter | -0.09 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 15.91%
Technicals Summary
Sell
Neutral
Buy
CTI BIOPHARMA CORP is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 CTI BIOPHARMA CORP | 85.07% | 51.34% | 52.36% | 66.36% | 66.36% |
 Moderna, Inc. | -4.27% | -29.63% | -10.94% | 105.39% | 586.61% |
 Regeneron Pharmaceuticals, Inc. | -8.82% | -3.37% | 11.63% | 22.7% | 139.69% |
 Seagen, Inc. | -1.74% | 61.71% | 45.87% | 23.07% | 217.59% |
 Vertex Pharmaceuticals Incorporated | -6.21% | 0.88% | 20.1% | 12.88% | 112.8% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
CTI BIOPHARMA CORP | NA | NA | 0.0 | -0.27 | -10.19 | -0.29 | 0.0 | -0.19 |
Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
Vertex Pharmaceuticals Incorporated | 26.15 | 26.15 | 0.41 | 14.62 | 0.26 | 0.17 | 0.0 | 56.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
CTI BIOPHARMA CORP | Buy | $1.2B | 66.36% | NA | -91.38% |
Moderna, Inc. | Buy | $49.1B | 586.61% | 11.46 | 31.77% |
Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 139.69% | 19.72 | 33.81% |
Seagen, Inc. | Hold | $36.7B | 217.59% | NA | -31.55% |
Vertex Pharmaceuticals Incorporated | Buy | $83.8B | 112.8% | 26.15 | 35.4% |
Institutional Holdings
State Street Corporation
9.43%Rubric Capital Management LP
6.80%Bvf Inc
6.68%BlackRock Inc
5.35%Stonepine Capital Management Llc
4.96%Vanguard Group Inc
4.52%
Company Information
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The company concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, the company has recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. The company's headquartered in Seattle, Washington.
Organization | CTI BIOPHARMA CORP |
Employees | 127 |
CEO | Dr. Adam R. Craig M.B.A., M.D., Ph.D. |
Industry | Health Technology |
